Congress·In Committee·H.R. 6867
NIH Clinical Trial Integrity Act
Congress targets more diverse NIH clinical trials with goals, public reporting, and outreach grants
Legislative Progress
House
Key Points
- Sponsors of NIH-approved clinical trials would have to set clear goals to enroll and keep participants that match the disease’s patient mix (or the U.S. population if unknown).
- Trial sponsors would have to regularly share participant counts and retention rates broken out by race, ethnicity, age, and sex, with privacy limits on shared data.
- If a trial misses its diversity goals by an agreed date, the sponsor must create and then carry out a public plan (with community groups) to improve participation.
- HHS would study ways to reduce cost barriers for volunteers, like paying back out-of-pocket costs and compensating people for their time, and whether rules need updating.
- HHS and FDA would run a national education campaign and give grants to nonprofits to boost awareness and recruitment; the bill authorizes $10 million a year for 2027–2030.
Impact Analysis
Personal Impact
How this policy affects specific groups of people
Positive Impacts(5)
Milestones
2 milestones2 actions
Dec 18, 2025
Referred to the House Committee on Energy and Commerce.
Dec 18, 2025
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
NIH Clinical Trial Integrity Act
Bill NumberHR 6867
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the House Committee on Energy and Commerce.
Data Sources
Sponsor
Cosponsors
(11)D: 10R: 1
Analysis generated by AI. Always verify with official sources.